Growth of REMS challenges FDA, stakeholders.
Traynor
Kate
K
D006801:Humans; D010353:Patient Education as Topic; D055553:Prescription Drugs / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing / Q000379:methods*; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D055553:Prescription Drugs